SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs about disclosure

26 Aug 2024 Evaluate
GlaxoSmithKline Pharmaceuticals has informed that the Company has received an Order dated 24th August 2024 from Punjab State GST authorities, dropping proceedings with respect to Show Cause Notice issued alleging non-payment of Cess amount disclosed in E-way bill.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2433.70 1.60 (0.07%)
21-Apr-2026 13:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.00
Dr. Reddys Lab 1221.25
Cipla 1230.95
Zydus Lifesciences 929.65
Lupin 2315.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×